Skip to main content

Peer Review reports

From: Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study

Original Submission
2 Jun 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
30 Oct 2021 Reviewed Reviewer Report
17 Jan 2022 Reviewed Reviewer Report - Santiago García López
6 Mar 2022 Author responded Author comments - Rogério Serafim Parra
Resubmission - Version 3
6 Mar 2022 Submitted Manuscript version 3
9 Mar 2022 Author responded Author comments - Rogério Serafim Parra
Resubmission - Version 4
9 Mar 2022 Submitted Manuscript version 4
13 Mar 2022 Reviewed Reviewer Report
2 Apr 2022 Author responded Author comments - Rogério Serafim Parra
Resubmission - Version 5
2 Apr 2022 Submitted Manuscript version 5
4 Apr 2022 Author responded Author comments - Rogério Serafim Parra
Resubmission - Version 6
4 Apr 2022 Submitted Manuscript version 6
5 Apr 2022 Author responded Author comments - Rogério Serafim Parra
Resubmission - Version 7
5 Apr 2022 Submitted Manuscript version 7
Publishing
12 Apr 2022 Editorially accepted
21 Apr 2022 Article published 10.1186/s12876-022-02280-3

You can find further information about peer review here.

Back to article page